Pharmacokinetics, Safety, and 48-Week Efficacy of Oral Raltegravir in HIV-1-Infected Children Aged 2 Through 18 YearsSharon Nachman, H. N. Ndiweni, Naiyu Zheng et al.|Clinical Infectious Diseases|2013Cited by 60
HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothersElizabeth J. McFarland, John S. Lambert, Daniel Johnson et al.|AIDS|2006Cited by 49
A Randomized, Open-Label Study of the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate in HIV-1–infected Children With Virologic SuppressionXavier Sáez‐Llorens, Martin S. Rhee, Dora Estripeaut et al.|The Pediatric Infectious Disease Journal|2014Cited by 19